| Title: | PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study |
| Journal: | Lancet Diabetes Endocrinol |
| Published: | 1 Feb 2017 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/27908689/ |
| DOI: | https://doi.org/10.1016/S2213-8587(16)30396-5 |
Publication 1683
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
Data were available for more than 550,000 individuals and 51,623 cases of type 2 diabetes. Combined analyses of four independent PCSK9 variants (rs11583680, rs11591147, rs2479409, and rs11206510) scaled to 1 mmol/L lower LDL cholesterol showed associations with increased fasting glucose (0 09 mmol/L, 95% CI 0 02 to 0 15), bodyweight (1 03 kg, 0 24 to 1 82), waist-to-hip ratio (0 006, 0 003 to 0 010), and an odds ratio for type diabetes of 1 29 (1 11 to 1 50). Based on the collected data, we did not identify associations with HbA1c (0 03%, -0 01 to 0 08), fasting insulin (0 00%, -0 06 to 0 07), and BMI (0 11 kg/m2, -0 09 to 0 30). PCSK9 variants associated with lower LDL cholesterol were also associated with circulating higher fasting glucose concentration, bodyweight, and waist-to-hip ratio, and an increased risk of type 2 diabetes. In trials of PCSK9 inhibitor drugs, investigators should carefully assess these safety outcomes and quantify the risks and benefits of PCSK9 inhibitor treatment, as was previously done for statins.1 Author
- Schmidt AF et al.
1 Application
| Application ID | Title |
|---|---|
| 7155 | Epidemiology of mental health, cognitive function, pain and cardiometabolic disease. |
Enabling scientific discoveries that improve human health